Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan

BackgroundMalignant melanoma occurs infrequently in Taiwan. Once it has progressed into osseous metastases, the prognosis is poor. There are no reported clinical experiences of surgical management in this area.MethodsTo improve our understanding of the rare clinical experiences, we retrospectively investigated clinical characteristics, radiological findings, treatment modalities, survival outcomes and prognoses of 11 Taiwanese patients with osseous metastasis of melanoma treated surgically at two national medical centers, National Taiwan University Hospital and National Cheng Kung University Hospital from January 1983 to December 2006.ResultsSix patients suffered from acral-lentiginous melanoma. Nine patients sustained multiple osseous metastases and most lesions were osteolytic. Nine patients also had sustained metastases to other organs including liver, lungs, lymph nodes, brain and spleen. Second malignancies including lung cancer, thyroid papillary carcinoma, renal cell carcinoma and cervical cancer co-existed in four patients. The interval from the initial diagnosis of melanoma to the clinical detection of osseous metastases varied from 0–37.8 months (mean 9.75 months). Metastatic melanoma was invariably fatal; the mean survival time from bone metastases to death was 5.67 months.ConclusionDue to the high morbidity and poor survival of Taiwanese patients with osseous metastases of melanoma, surgical treatment should be directed towards pain relief and the prevention of skeletal debilitation in order to maintain their quality of life.

[1]  Chun-Ying Wu,et al.  Clinicopathologic analysis of malignant melanoma in Taiwan. , 1999, Journal of the American Academy of Dermatology.

[2]  C. Harmer,et al.  Spontaneous regression of multiple bone metastases in malignant melanoma. , 1989, British Journal of Radiology.

[3]  D. Morton,et al.  Prognostic factors in 1,521 melanoma patients with distant metastases. , 1995, Journal of the American College of Surgeons.

[4]  P. Wiffen,et al.  Bisphosphonates for the relief of pain secondary to bone metastases. , 2002, The Cochrane database of systematic reviews.

[5]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[6]  C. Riebeling,et al.  The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro , 2002, British Journal of Cancer.

[7]  D. Reintgen,et al.  Recurrent malignant melanoma: the identification of prognostic factors to predict survival. , 1992, Annals of plastic surgery.

[8]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[9]  J. Naeyaert,et al.  Understanding the trends in melanoma incidence and mortality: where do we stand? , 2000, European journal of dermatology : EJD.

[10]  B. Lamm,et al.  Metastatic malignant melanoma to the foot and ankle: a review of the literature and case report. , 2000, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[11]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[12]  L. Wold,et al.  Malignant melanoma metastatic to bone. , 1992, Orthopedics.

[13]  W. Hohenberger,et al.  Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. , 1999, International journal of radiation oncology, biology, physics.

[14]  M. Atkins,et al.  The treatment of metastatic melanoma with chemotherapy and biologics. , 1997, Current opinion in oncology.

[15]  H. Schwartz,et al.  Heterogeneous Survival Rates for Isolated Skeletal Metastases From Melanoma , 1996, Clinical orthopaedics and related research.

[16]  M. Kersten,et al.  Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma , 2003, British Journal of Cancer.

[17]  D. Miller,et al.  Update on the incidence and mortality from melanoma in the United States. , 1999, Journal of the American Academy of Dermatology.

[18]  D. Reintgen,et al.  Metastatic melanoma: chemotherapy to biochemotherapy. , 2002, Cancer control : journal of the Moffitt Cancer Center.

[19]  R. Yokoyama,et al.  Primary malignant melanoma (clear cell sarcoma) of bone: Report of a case arising in the ulna , 1996, Cancer.

[20]  H. Jaeger,et al.  Patellar metastasis from a malignant melanoma , 2004, International Orthopaedics.

[21]  J. Berenson Recommendations for zoledronic acid treatment of patients with bone metastases. , 2005, The oncologist.

[22]  R. Essner,et al.  The role of surgery in treatment of stage IV melanoma , 2006, Journal of surgical oncology.

[23]  S. Aoyagi,et al.  Pedunculated Melanoma with Pulmonary and Bony Metastases , 2000, Journal of dermatology (Print).

[24]  Intra-articular metastatic melanoma of the right knee. , 1999, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.